Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group

JAMA. 1992 Jul;268(4):483-8. doi: 10.1001/jama.268.4.483.

Abstract

Objective: To evaluate the efficacy of intravenous immunoglobulin (IVIG) for prevention of viral, opportunistic, and minor bacterial infections in children infected with human immunodeficiency virus (HIV).

Design: Randomized, double-blind, placebo-controlled, outpatient clinical trial comparing subjects treated with 400 mg of IVIG per kilogram of body weight every 28 days with those given albumin placebo.

Setting: Twenty-eight clinical centers in mainland United States and Puerto Rico.

Patients: Three hundred seventy-six children infected with human immunodeficiency virus with clinical or immunologic evidence of HIV disease, 313 of whom had entry CD4+ counts of at least 0.20 x 10(9)/L (greater than or equal to 200/mm3).

Main outcome measures: The incidence of laboratory-proven and clinically diagnosed viral, opportunistic, and bacterial infections.

Main results: Viral infections and minor bacterial infections contributed more frequently to morbidity in children with entry CD4+ counts of at least 0.20 x 10(9)/L (together over five times as frequent) than did serious bacterial infection, the primary outcome measure of the trial. Opportunistic infections occurred at a similar rate as laboratory-proven serious bacterial infections. In this group of children, IVIG was significantly associated with a decrease in the rate of viral infections and minor bacterial infections per 100 patient-years (36.0 vs 54.0 episodes of viral infection per 100 patient-years, IVIG vs placebo, P = .01; and 115.1 vs 159.7 episodes of minor bacterial infection per 100 patient-years, IVIG vs placebo, P = .02), as well as a decrease in the rate of serious bacterial infections per 100 patient-years (26.4 vs 48.2 episodes per 100 patient-years; P = .002). There was no apparent difference in the rate of opportunistic infections between treatment arms.

Conclusions: Beneficial effect of IVIG was seen across multiple infectious outcome measures, with reductions in serious and minor viral and bacterial infections observed in children with entry CD4+ counts of at least 0.20 x 10(9)/L.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Bacterial Infections / complications
  • Bacterial Infections / prevention & control
  • CD4-Positive T-Lymphocytes*
  • Child, Preschool
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • HIV Infections / complications
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Incidence
  • Leukocyte Count
  • Male
  • Opportunistic Infections / complications
  • Opportunistic Infections / prevention & control*
  • Pneumonia, Pneumocystis / prevention & control
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Virus Diseases / complications
  • Virus Diseases / prevention & control

Substances

  • Immunoglobulins, Intravenous
  • Trimethoprim, Sulfamethoxazole Drug Combination